4:02 PM ET
10-Q
Financial Results
IGC Pharma Q3 2026 Results: Net Loss of $2.05M, Loss Widens
IGC Pharma, Inc. reported a net loss of $7.38 million for the nine months ended September 30, 2026, compared to a $4.62 million loss in the prior year period. While revenue increased slightly to $910,000, the company's operating loss widened due to higher research and development and administrative expenses related to its clinical trials.
- Key figure
- Net loss $2.05M